NewAmsterdam Pharma Company NV
NASDAQ:NAMS

  • LAST PRICE
    18.0300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    15.3200/ 10
  • Ask / Lots
    28.8400/ 2
  • Open / Previous Close
    --- / 18.0300
  • Day Range
    ---
  • 52 Week Range
    8.6400
    26.3500
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 1, 2024

      Show headlines and story abstract

    • 5:26PM ET on Friday Nov 01, 2024 by Dow Jones
      Companies Mentioned: NAMS

      NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 97,600 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the "2024 Inducement Plan") and in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Oct 28, 2024

      Show headlines and story abstract

    • 4:30PM ET on Monday Oct 28, 2024 by Dow Jones
      Companies Mentioned: NAMS

      NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

      NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from the pivotal Phase 3 BROOKLYN study evaluating obicetrapib in patients with Heterozygous Familial Hypercholesterolemia in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 -- 18, 2024 in Chicago, Illinois. Additionally, NewAmsterdam announced that company management will participate in the Jefferies London Healthcare Conference, taking place November 19 -- 21, 2024 in London. Details are as follows:

Peers Headlines